VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383 on ClinicalTrials.gov · last registry update 2026-04-07
An unusually large phase 3: 1,100 participants, more than double the 424 typical for the stage. Due to report 1 July 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Percent change in body weight from baseline to Week 78 in body weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. VK2735 is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P3
- Drug
- VK2735
- Sponsor
- Viking Therapeutics, Inc.
- Sponsor type
- Industry
- Enrollment
- 1,100
- Started
- 2025-06-23
- Primary completion
- 2027-07-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent change in body weight from baseline to Week 78 in body weight
Conditions studied
Weight Loss
Every field above is taken directly from the registry record. See all detected changes across the class, or the VK2735 page for this molecule’s full trial and approval history.